United BioSource

Micromyx is a microbiology services company engaged in anti-infective discovery and development for the pharmaceutical, biotechnology, and animal health industries. Founded in 2004 by former pharmaceutical industry infectious disease scientists, Micromyx is a contract research organization that aims to offer clients documented, top-of-the-line laboratory services from experts who have successfully gained FDA approval of new antibiotics.

Sai Life Sciences offers their clients a wide range of integrated drug discovery, development and formulation services, with core expertise founded in synthetic, medicinal and process chemistry and further augmented by a suite of preclinical support services including DMPK, toxicology and formulation that are continually expanding to meet clients' needs.

Veratect offers services that aim to offer the early detection, 24/7 tracking and actionable alert generation of emerging threats (pandemics) worldwide. The company offers the Foreshadow and VeraSight. Per the company, Veratect provides timely and actionable information that supports informed decisions across a broad range of public and private institutions. By identifying emerging risks early, Veratect contends that actions can be taken that save human life, enable loss control, preserve business processes, safeguard supply chain operations and facilities, better manage financial reporting and insurance coverage, and mitigate potential class action lawsuits due to negligence in responding to threats in a timely manner.

Renovo Research is a contract research lab that specializes in crystal form discovery for the pharmaceutical industry.

StemCyte, Inc. is a umbilical cord blood ("UCB") stem cell transplantation and therapeutic products company. StemCyte, headquartered in Southern California has UCB storage facilities in both California and Taiwan which collect, process and store UCB stem cells to be used as therapeutic treatments.

Bridge Laboratories is a preclinical contract research organization (CRO) that aims to provide US-level regulatory compliant drug development services globally. Bridge is US-owned and is headquartered in Gaithersburg, Maryland, with lab facilities in the US and Beijing, China. Bridge is known for its work in toxicology; including a wide variety of in vivo toxicology studies that examine the effect on the immune system, vaccines, developmental and reproductive toxicology, and safety pharmacology. Bridge's AAALAC accredited facility in China was among a labs to perform GLP studies for clients worldwide.